WINTON GROUP Ltd Has $5.43 Million Stock Holdings in Exelixis, Inc. $EXEL

Key Points

• WINTON GROUP Ltd increased its Exelixis stake by 1,651.5% in the second quarter, acquiring 94,134 additional shares for a total holding worth approximately $5.43 million. Institutional investors and hedge funds collectively own 85.27% of EXEL.
• Analyst sentiment is mixed, with Exelixis receiving an average “Hold” rating and a consensus price target of $50.07. Recent target prices range from $49 to $52, while ratings include one Strong Buy, six Buys, twelve Holds and one Sell.
• Exelixis reported quarterly EPS of $0.91, beating expectations of $0.85, while revenue rose 10.6% year over year to $628.69 million, slightly below estimates. The stock opened at $57.43, near its 52-week high of $59.72.

WINTON GROUP Ltd boosted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1,651.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 99,834 shares of the biotechnology company's stock after acquiring an additional 94,134 shares during the period. WINTON GROUP Ltd's holdings in Exelixis were worth $5,432,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. Squarepoint Ops LLC boosted its stake in shares of Exelixis by 1,649.8% in the 2nd quarter. Squarepoint Ops LLC now owns 473,707 shares of the biotechnology company's stock valued at $25,774,000 after purchasing an additional 446,635 shares during the last quarter. Baird Financial Group Inc. raised its stake in shares of Exelixis by 7,459.0% during the second quarter. Baird Financial Group Inc. now owns 437,138 shares of the biotechnology company's stock worth $23,785,000 after buying an additional 431,355 shares during the last quarter. Allworth Financial LP raised its stake in shares of Exelixis by 4.7% during the second quarter. Allworth Financial LP now owns 10,562 shares of the biotechnology company's stock worth $575,000 after buying an additional 478 shares during the last quarter. Waverly Advisors LLC lifted its holdings in Exelixis by 4.0% in the second quarter. Waverly Advisors LLC now owns 13,174 shares of the biotechnology company's stock valued at $717,000 after buying an additional 509 shares during the period. Finally, Nykredit A S acquired a new position in Exelixis in the second quarter valued at approximately $474,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on EXEL shares. Leerink Partners cut shares of Exelixis from an "outperform" rating to a "market perform" rating and set a $52.00 target price for the company. in a research report on Thursday, August 6th. Truist Financial decreased their price objective on Exelixis from $56.00 to $52.00 and set a "hold" rating for the company in a research note on Thursday, August 6th. Wells Fargo & Company upped their price objective on Exelixis from $40.00 to $49.00 and gave the company an "equal weight" rating in a report on Monday, July 13th. Zacks Research raised Exelixis from a "strong sell" rating to a "hold" rating in a research note on Tuesday, September 1st. Finally, Citigroup restated a "market outperform" rating on shares of Exelixis in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Exelixis presently has an average rating of "Hold" and a consensus target price of $50.07.

Insider Transactions at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares of the company's stock, valued at approximately $862,799.14. This represents a 37.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company's stock.

Exelixis Trading Down 1.5%

EXEL stock opened at $57.43 on Friday. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $59.72. The firm has a market cap of $14.23 billion, a PE ratio of 18.06, a P/E/G ratio of 1.73 and a beta of 0.42. The business's 50-day moving average price is $55.34 and its two-hundred day moving average price is $49.94.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.06. The company had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.75 earnings per share. On average, analysts forecast that Exelixis, Inc. will post 3.19 earnings per share for the current year.

About Exelixis

Exelixis, Inc NASDAQ: EXEL is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company's research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and progression.

Exelixis' principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine-refractory differentiated thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.